P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1G
12 ott, 09:49:20 GMT+8 · SGD
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per P8A in corso…
Cap. mercato
32,37 Mln
Vol. medio
1,32K
Volume
0,00
Max 52 sett.
0,26 SGD
Min 52 sett.
0,10 SGD
Utili per azione
-0,04 SGD
Azioni in circolazione
267,53 Mln
N. di dipendenti
111
Cap. mercato
32,37 Mln
Vol. medio
1,32K
Volume
0,00
Max 52 sett.
0,26 SGD
Min 52 sett.
0,10 SGD
Utili per azione
-0,04 SGD
Azioni in circolazione
267,53 Mln
N. di dipendenti
111
Articoli giornalistici
Da fonti web e partner giornalistici
Investing.com
·
56 minuti fa
Il Dow balza di 556 punti mentre Nvidia cede, la nostra IA l’aveva previsto
MarketScreener Italia
·
7 ore fa
Il Dow interrompe la flessione di due giorni mentre la Borsa rimbalza nonostante i timori sull'inflazione
MarketScreener Italia
·
15 ore fa
USA: l'indice della Federal Reserve di New York supera nettamente le attese
Profilo
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Informazioni su Cordlife Group Ltd